X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-21 | AUPH | Aurinia Pharmaceuticals Inc. | Robertson Stephen P. | GC | S - Sale | $16.97 | -20,975 | 600,787 | -3% | -$355,946 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Hohenleitner Susan | CFO | S - Sale | $3.86 | -1,558 | 227,520 | -1% | -$6,009 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Reilly Joseph James | See Remarks | S - Sale | $3.86 | -3,982 | 145,854 | -3% | -$15,358 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Bishop John E | See Remarks | S - Sale | $3.86 | -19,750 | 317,095 | -6% | -$76,174 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Brady James Parker | CHRO | S - Sale | $3.86 | -15,136 | 245,930 | -6% | -$58,378 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $3.86 | -8,562 | 409,410 | -2% | -$33,023 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Kelliher Mike | Chief Business Officer | S - Sale | $3.86 | -7,758 | 349,660 | -2% | -$29,922 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale | $3.86 | -10,739 | 367,456 | -3% | -$41,419 | ||||||
2026-08-21 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $3.86 | -58,574 | 1,645,156 | -3% | -$225,914 | ||||||
| DM | 2026-08-21 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $18.96 | -10,906 | 0 | -100% | -$206,805 | |||||
2026-08-21 | PGEN | Precigen, Inc. | Agee Nancy H | Dir | P - Purchase | $7.23 | +3,411 | 309,187 | +1% | +$24,662 | ||||||
| DM | 2026-08-21 | PGEN | Precigen, Inc. | Shah Rutul R | COO | S - Sale+OE | $7.50 | -50,000 | 468,865 | -10% | -$375,000 | |||||
| D | 2026-08-25 | PGEN | Precigen, Inc. | Tennant Phil | Chief Commercial Officer | S - Sale+OE | $7.50 | -79,166 | 141,992 | -36% | -$593,745 | |||||
| D | 2026-08-21 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale+OE | $25.98 | -7,437 | 38,400 | -16% | -$193,189 | |||||
| D | 2026-08-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $511.97 | -9,500 | 668,728 | -1% | -$4,863,730 | |||||
| D | 2026-08-21 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $69.09 | -73,631 | 174,606 | -30% | -$5,087,225 | |||||
| D | 2026-08-24 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale+OE | $26.91 | -125,000 | 122,802 | -50% | -$3,363,750 | |||||
2026-08-21 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $15.54 | -9,589 | 63,899 | -13% | -$149,013 | ||||||
2026-08-21 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $15.54 | -989 | 16,816 | -6% | -$15,369 | ||||||
| D | 2026-08-21 | TEVA | Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | S - Sale+OE | $37.62 | -9,445 | 13,071 | -42% | -$355,301 | |||||
2026-08-21 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $15.54 | -1,457 | 16,220 | -8% | -$22,642 | ||||||
2026-08-21 | TEVA | Teva Pharmaceutical Industries Ltd | Satchi-Fainaro Ronit | Dir | S - Sale | $37.25 | -415 | 111,986 | 0% | -$15,459 | ||||||
| DM | 2026-08-20 | PRE | Prenetics Global Ltd | Yeung Danny Sheng Wu | CEO | P - Purchase | $20.34 | +24,681 | 112,416 | +28% | +$501,998 | |||||
2026-08-24 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +2,100 | 9,360,756 | 0% | +$116 | ||||||
| M | 2026-08-20 | TENX | Tenax Therapeutics, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.77 | +1,025,867 | 4,853,818 | +27% | +$1,814,147 | |||||
| D | 2026-08-21 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale+OE | $30.00 | -2,827 | 39,581 | -7% | -$84,810 | |||||
2026-08-24 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $12.39 | +100,000 | 1,214,650 | +9% | +$1,239,000 | ||||||
2026-08-21 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $11.89 | -4,345 | 169,269 | -3% | -$51,663 | ||||||
2026-08-24 | ABCL | Abcellera Biologics Inc. | Hayden Michael R | Dir | P - Purchase | $10.64 | +53,613 | 1,491,642 | +4% | +$570,442 | ||||||
| D | 2026-08-24 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | S - Sale+OE | $65.07 | -25,000 | 37,025 | -40% | -$1,626,750 | |||||
2026-08-20 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $47.05 | -60,677 | 59,086 | -51% | -$2,854,853 | ||||||
| D | 2026-08-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $518.39 | -9,500 | 668,728 | -1% | -$4,924,666 | |||||
| D | 2026-08-20 | ARQT | Arcutis Biotherapeutics, Inc. | Curran Terrie | Dir | S - Sale+OE | $26.04 | -1,072 | 23,526 | -4% | -$27,912 | |||||
2026-08-20 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.37 | +11,899 | 600,117 | +2% | +$16,302 | ||||||
2026-08-21 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.65 | +20,000 | 73,533 | +37% | +$13,000 | ||||||
2026-08-20 | TNXP | Tonix Pharmaceuticals Holding Corp. | Bagger Richard H | Dir | P - Purchase | $12.60 | +1,000 | 1,000 | New | +$12,600 | ||||||
| DM | 2026-08-19 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | S - Sale+OE | $36.88 | -335,174 | 18,630,739 | -2% | -$12,360,813 | |||||
2026-08-19 | AEON | Aeon Biopharma, Inc. | Lynch Timothy P | 10% | P - Purchase | $0.21 | +1,150,000 | 6,500,000 | +21% | +$243,455 | ||||||
| D | 2026-08-19 | MANE | Veradermics, Inc | Montanova Capital, LLC | Dir | S - Sale+OE | $107.25 | -750,000 | 612,033 | -55% | -$80,437,500 | |||||
| D | 2026-08-20 | OMER | Omeros Corp | Cable Thomas J. | Dir | S - Sale+OE | $18.45 | -15,000 | 35,067 | -30% | -$276,773 | |||||
| M | 2026-08-19 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $72.22 | -25,000 | 1,524,860 | -2% | -$1,805,411 | |||||
| M | 2026-08-19 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir | S - Sale | $4.59 | -191,865 | 5,677,226 | -3% | -$879,719 | |||||
| D | 2026-08-19 | NUVB | Nuvation Bio Inc. | Hattersley Gary | Chief Scientific Officer | S - Sale+OE | $7.09 | -100,000 | 0 | -100% | -$709,240 | |||||
| D | 2026-08-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $521.02 | -9,500 | 668,728 | -1% | -$4,949,717 | |||||
| D | 2026-08-20 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $523.14 | -8,300 | 45,172 | -16% | -$4,342,079 | |||||
2026-08-19 | TAK | Takeda Pharmaceutical Co Ltd | Plump Andrew Stewart | Pres, R, D | S - Sale | $18.49 | -19,651 | 1,028,225 | -2% | -$363,347 | ||||||
2026-08-19 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $12.63 | -31,487 | 195,444 | -14% | -$397,681 | ||||||
| DM | 2026-08-19 | LQDA | Liquidia Corp | Rielly-Gauvin Katherine | Dir | S - Sale+OE | $74.07 | -55,182 | 44,637 | -55% | -$4,087,435 | |||||
2026-08-19 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.00 | -28,468 | 141,053 | -17% | -$398,552 | ||||||
2026-08-20 | ELAN | Elanco Animal Health Inc | Kurzius Lawrence Erik | Dir | P - Purchase | $23.40 | +40,000 | 188,647 | +27% | +$935,920 | ||||||
2026-08-19 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale | $27.00 | -260 | 35,635 | -1% | -$7,020 | ||||||
2026-08-19 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $27.00 | -1,697 | 117,592 | -1% | -$45,819 | ||||||
2026-08-20 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.79 | +50,000 | 935,500 | +6% | +$439,430 | ||||||
2026-08-18 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | P - Purchase | $5.49 | +12,757 | 4,674,788 | 0% | +$69,998 | ||||||
| AM | 2026-04-10 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | Chief Scientific Officer, 10% | P - Purchase | $4.09 | +47,207 | 4,671,083 | +1% | +$192,899 | |||||
2026-08-20 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.59 | +16,634 | 53,533 | +45% | +$9,811 | ||||||
| D | 2026-08-19 | VRDN | Viridian Therapeutics, Inc.De | Tousignant Jennifer | GC | S - Sale+OE | $24.50 | -14,212 | 0 | -100% | -$348,194 | |||||
2026-08-18 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $71.98 | -186 | 9,570 | -2% | -$13,388 | ||||||
2026-08-18 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $71.98 | -418 | 54,655 | -1% | -$30,088 | ||||||
| M | 2026-08-19 | ETON | Eton Pharmaceuticals, Inc. | Brynjelsen Sean | Pres, CEO | S - Sale | $60.88 | -100,000 | 961,194 | -9% | -$6,087,773 | |||||
2026-08-19 | MGNX | Macrogenics Inc | Peters Jeffrey Stuart | SVP, GC,, Secretary | S - Sale | $4.15 | -31,105 | 0 | -100% | -$129,086 | ||||||
| M | 2026-08-18 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $0.37 | -375,840 | 9,305,923 | -4% | -$140,313 | |||||
| M | 2026-08-18 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $0.37 | -375,840 | 9,305,923 | -4% | -$140,313 | |||||
2026-08-18 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.38 | -631 | 673,853 | 0% | -$2,133 | ||||||
2026-08-18 | ARWR | Arrowhead Pharmaceuticals, Inc. | Olukotun Adeoye Y | Dir | S - Sale | $86.96 | -2,000 | 31,600 | -6% | -$173,920 | ||||||
2026-08-18 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.38 | -2,293 | 1,462,832 | 0% | -$7,753 | ||||||
2026-08-18 | ARWR | Arrowhead Pharmaceuticals, Inc. | Perry Michael S | Dir | S - Sale | $87.30 | -11,600 | 111,459 | -9% | -$1,012,680 | ||||||
| D | 2026-08-19 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $526.96 | -9,500 | 668,728 | -1% | -$5,006,104 | |||||
2026-08-19 | BHC | Bausch Health Companies Inc. | Lenar Aimee J. | Pres, US Pharma | S - Sale | $7.03 | -36,827 | 334,853 | -10% | -$258,894 | ||||||
| M | 2026-08-18 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $82.86 | -44,980 | 5,067,460 | -1% | -$3,727,251 | |||||
2026-08-18 | CORT | Corcept Therapeutics Inc | Mahoney David L | Dir | S - Sale | $118.25 | -103,606 | 1,159,686 | -8% | -$12,251,411 | ||||||
2026-08-17 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale | $514.97 | -664 | 11,474 | -5% | -$341,940 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Peterson Katharine | Chief Accounting Officer | S - Sale | $2.01 | -101 | 18,033 | -1% | -$203 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Tanini Annita | Corp. Controller, VP, Finance | S - Sale | $10.29 | -1,224 | 45,144 | -3% | -$12,595 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Lerner Lorena Raquel | Chief Scientific Officer | S - Sale | $10.29 | -3,568 | 27,559 | -11% | -$36,715 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Cho Esther | GC | S - Sale | $10.29 | -4,485 | 35,770 | -11% | -$46,151 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Newton Charles W. | Dir | S - Sale | $10.30 | -551 | 12,114 | -4% | -$5,675 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | GC | S - Sale | $2.01 | -185 | 82,009 | 0% | -$372 | ||||||
2026-08-19 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $49.90 | -404 | 246,022 | 0% | -$20,160 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Officer | S - Sale | $2.01 | -400 | 52,592 | -1% | -$804 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | S - Sale | $2.01 | -604 | 146,349 | 0% | -$1,214 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO | S - Sale | $2.01 | -1,713 | 2,629,947 | 0% | -$3,443 | ||||||
| D | 2026-08-19 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $152.21 | -4,302 | 0 | -100% | -$654,791 | |||||
2026-08-20 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +11,500 | 9,378,656 | 0% | +$518 | ||||||
2026-08-19 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.35 | +2,700 | 36,899 | +8% | +$945 | ||||||
2026-08-19 | PHIO | Phio Pharmaceuticals Corp. | Plott Ronald Todd | Dir | P - Purchase | $1.14 | +15,000 | 15,000 | New | +$17,100 | ||||||
2026-08-19 | CAMP | Camp4 Therapeutics Corp | Tardiff Daniel | Chief Scientific Officer | S - Sale | $4.76 | -1,738 | 0 | -100% | -$8,273 | ||||||
| DM | 2026-08-17 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $75.09 | -79,534 | 142,265 | -36% | -$5,972,206 | |||||
| D | 2026-08-18 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $100.00 | -40,000 | 1,274 | -97% | -$4,000,000 | |||||
2026-08-14 | ZNTL | Zentalis Pharmaceuticals, Inc. | Walters Group | 10% | P - Purchase | $3.50 | +4,335,000 | 17,844,973 | +32% | +$15,172,500 | ||||||
| D | 2026-08-19 | DNTH | Dianthus Therapeutics, Inc. /De/ | Read Simon | Dir | S - Sale+OE | $117.55 | -2,778 | 0 | -100% | -$326,554 | |||||
2026-08-17 | ANTX | An2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.01 | -35,402 | 642,944 | -5% | -$212,702 | ||||||
| D | 2026-08-17 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $72.57 | -2,813 | 105,272 | -3% | -$204,127 | |||||
| D | 2026-08-17 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $26.18 | -4,730 | 36,475 | -11% | -$123,835 | |||||
2026-08-17 | NATR | Natures Sunshine Products Inc | Prescott Group Capital Management, L.L.C. | 10% | P - Purchase | $14.69 | +20,000 | 1,944,486 | +1% | +$293,800 | ||||||
| D | 2026-08-18 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $515.60 | -9,500 | 668,728 | -1% | -$4,898,221 | |||||
2026-08-18 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $59.97 | -100,000 | 393,601 | -20% | -$5,997,250 | ||||||
2026-08-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale | $58.58 | -6,018 | 40,036 | -13% | -$352,551 | ||||||
| D | 2026-08-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | S - Sale+OE | $58.59 | -5,000 | 25,000 | -17% | -$292,931 | |||||
2026-08-18 | TAK | Takeda Pharmaceutical Co Ltd | Greenway Nicola Deidre Petal | CHRO | S - Sale | $18.11 | -12,980 | 40,049 | -24% | -$235,118 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |